RELV vs. IBIO, AEON, NRBO, OBSV, CPHI, GRAY, ATXI, ORGS, CANF, and ADXS
Should you be buying Reliv' International stock or one of its competitors? The main competitors of Reliv' International include iBio (IBIO), AEON Biopharma (AEON), NeuroBo Pharmaceuticals (NRBO), ObsEva (OBSV), China Pharma (CPHI), Graybug Vision (GRAY), Avenue Therapeutics (ATXI), Orgenesis (ORGS), Can-Fite BioPharma (CANF), and Ayala Pharmaceuticals (ADXS).
Reliv' International vs. Its Competitors
Reliv' International (NASDAQ:RELV) and iBio (NYSE:IBIO) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.
Reliv' International has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Comparatively, iBio has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.
8.0% of Reliv' International shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 31.2% of Reliv' International shares are held by insiders. Comparatively, 2.8% of iBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Reliv' International has higher revenue and earnings than iBio.
In the previous week, iBio had 4 more articles in the media than Reliv' International. MarketBeat recorded 4 mentions for iBio and 0 mentions for Reliv' International. Reliv' International's average media sentiment score of 0.00 equaled iBio'saverage media sentiment score.
iBio has a consensus price target of $3.50, indicating a potential upside of 291.94%. Given iBio's stronger consensus rating and higher probable upside, analysts plainly believe iBio is more favorable than Reliv' International.
iBio has a net margin of 0.00% compared to Reliv' International's net margin of -0.61%. Reliv' International's return on equity of -1.89% beat iBio's return on equity.
Summary
iBio beats Reliv' International on 8 of the 14 factors compared between the two stocks.
Get Reliv' International News Delivered to You Automatically
Sign up to receive the latest news and ratings for RELV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RELV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Reliv' International Competitors List
Related Companies and Tools
This page (NASDAQ:RELV) was last updated on 10/20/2025 by MarketBeat.com Staff